{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:35Z","timestamp":1786984295524,"version":"build-2736575974"},"reference-count":253,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020180","name":"Japanese Society of Allergology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.alit.2024.08.008","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:49:31Z","timestamp":1729082971000},"page":"51-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody"],"prefix":"10.1016","volume":"74","author":[{"given":"Hiroaki","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2024.08.008_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","article-title":"Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD","volume":"68","author":"Taniguchi","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMcibr1514013","article-title":"Aspirin-exacerbated respiratory disease--new prime suspects","volume":"374","author":"Laidlaw","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.08.008_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","article-title":"Updates on immune mechanisms in aspirin-exacerbated respiratory disease","volume":"151","author":"Laidlaw","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.08.008_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1067\/mai.2003.1487","article-title":"Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management","volume":"111","author":"Szczeklik","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaip.2016.10.021","article-title":"Current knowledge and management of hypersensitivity to aspirin and NSAIDs","volume":"5","author":"Laidlaw","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaci.2006.07.024","article-title":"Clinical and pathologic perspectives on aspirin sensitivity and asthma","volume":"118","author":"Stevenson","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2019.08.022","article-title":"Aspirin sensitivity: lessons in the regulation (and dysregulation) of mast cell function","volume":"144","author":"Boyce","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI620","article-title":"Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma","volume":"101","author":"Cowburn","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2024.08.008_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1164\/ajrccm.153.1.8542168","article-title":"Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects","volume":"153","author":"Nasser","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"6 Pt 1","key":"10.1016\/j.alit.2024.08.008_bib13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/0091-6749(94)90123-6","article-title":"Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma","volume":"94","author":"Fischer","year":"1994","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4168\/aair.2022.14.2.153","article-title":"Emerging biomarkers beyond leukotrienes for the management of nonsteroidal anti-inflammatory drug (NSAID)-Exacerbated respiratory disease","volume":"14","author":"Rhyou","year":"2022","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.alit.2024.08.008_bib15","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5R\u03b1 marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2016.04.028","article-title":"Eosinophilia-associated coronary artery vasospasm in patients with aspirin-exacerbated respiratory disease","volume":"4","author":"Shah","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib17","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.jaip.2020.06.061","article-title":"Leukotriene-associated rash in aspirin-exacerbated respiratory disease","volume":"8","author":"Laidlaw","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib18","first-page":"159","article-title":"Glucocorticosteroids attenuate aspirin-precipitated adverse reactions in aspirin-intolerant patients with asthma","volume":"63","author":"Nizankowska","year":"1989","journal-title":"Ann Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1081-1206(10)61150-7","article-title":"The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease","volume":"95","author":"White","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib20","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group","volume":"341","author":"Milgrom","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"8 Pt 2","key":"10.1016\/j.alit.2024.08.008_bib21","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","article-title":"Anti-immunoglobulin E (omalizumab) therapy in allergic asthma","volume":"164","author":"Busse","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.alit.2019.01.004","article-title":"Biological treatments for severe asthma: a major advance in asthma care","volume":"68","author":"Busse","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib24","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.jaci.2022.03.029","article-title":"Advances in mast cell biology","volume":"149","author":"Boyce","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib26","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9alpha,11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib27","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jaip.2022.06.016","article-title":"The role of omalizumab in NSAID-exacerbated respiratory disease: a narrative review","volume":"10","author":"Taniguchi","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib28","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jaci.2023.03.014","article-title":"Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease","volume":"151","author":"Hayashi","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5 Pt 1","key":"10.1016\/j.alit.2024.08.008_bib29","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025","article-title":"Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects","volume":"143","author":"Christie","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.alit.2024.08.008_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1164\/rccm.201904-0716ED","article-title":"Aspirin-exacerbated respiratory disease: a syndrome of mast cell-mediated PgD2 overproduction","volume":"200","author":"Borish","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1164\/ajrccm.160.1.9808048","article-title":"Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics","volume":"160","author":"Picado","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1183\/09031936.93.05060693","article-title":"Urinary leukotriene E4 in bronchial asthma","volume":"5","author":"Smith","year":"1992","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.08.008_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2332\/allergolint.08-RAI-0040","article-title":"Hyperleukotrieneuria in patients with allergic and inflammatory disease","volume":"57","author":"Taniguchi","year":"2008","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaci.2013.03.048","article-title":"Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production","volume":"132","author":"Doherty","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib35","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.4049\/jimmunol.176.7.4440","article-title":"Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation","volume":"176","author":"Kim","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1183\/09031936.93.06030391","article-title":"Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma","volume":"6","author":"Sladek","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.08.008_bib37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.4049\/jimmunol.173.3.1503","article-title":"Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses","volume":"173","author":"Kanaoka","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib38","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","article-title":"Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes","volume":"119","author":"Laidlaw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.alit.2024.08.008_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7224","article-title":"Airway brush cells generate cysteinyl leukotrienes through the ATP sensor P2Y2","volume":"5","author":"Ualiyeva","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1398-9995.1997.tb00966.x","article-title":"Measurements of leukotrienes in the urine: strategies and applications","volume":"52","author":"Kumlin","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib41","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jaci.2009.12.977","article-title":"Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers","volume":"125","author":"Higashi","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib42","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1067\/mai.2002.124466","article-title":"Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma","volume":"109","author":"Kawagishi","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib43","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaip.2016.11.004","article-title":"Urinary leukotriene E4 to determine aspirin intolerance in asthma: a systematic review and meta-analysis","volume":"5","author":"Hagan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib44","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/cea.14362","article-title":"Long-term clinical outcomes of aspirin-exacerbated respiratory disease: real-world data from an adult asthma cohort","volume":"53","author":"Lee","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaci.2003.10.068","article-title":"Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis","volume":"113","author":"Higashi","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2332\/allergolint.11-RA-0403","article-title":"Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites","volume":"61","author":"Higashi","year":"2012","journal-title":"Allergol Int"},{"issue":"3 Pt 1","key":"10.1016\/j.alit.2024.08.008_bib47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-6749(99)70324-6","article-title":"Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses","volume":"104","author":"Daffern","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib48","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jaip.2018.12.014","article-title":"Sinus surgery is associated with a decrease in aspirin-induced reaction severity in patients with aspirin exacerbated respiratory disease","volume":"7","author":"Jerschow","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1183\/09031936.95.08030411","article-title":"Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor","volume":"8","author":"Johnston","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.08.008_bib50","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1398-9995.2001.00913.x","article-title":"Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma","volume":"56","author":"Mita","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000087571","article-title":"Eicosanoid mediators of mast cells: receptors, regulation of synthesis, and pathobiologic implications","volume":"87","author":"Boyce","year":"2005","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0090-6980(98)00076-8","article-title":"Analyses of prostaglandin D2 metabolites in urine: comparison between enzyme immunoassay and negative ion chemical ionisation gas chromatography-mass spectrometry","volume":"57","author":"O'Sullivan","year":"1999","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.alit.2024.08.008_bib53","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/thx.2004.026641","article-title":"Monitoring mast cell activation by prostaglandin D2 in\u00a0vivo","volume":"59","author":"Dahlen","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2024.08.008_bib54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejphar.2011.07.046","article-title":"Prostaglandin D\u2082 induces contractions through activation of TP receptors in peripheral lung tissue from the Guinea pig","volume":"669","author":"Larsson","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.alit.2024.08.008_bib55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaci.2011.09.019","article-title":"Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis","volume":"129","author":"Higashi","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib56","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1074\/jbc.M706839200","article-title":"Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans","volume":"283","author":"Song","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.alit.2024.08.008_bib57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1067\/mai.2003.1387","article-title":"A\u00a0controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge","volume":"111","author":"Bochenek","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib58","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib59","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(95)90409-3","article-title":"Bronchoprotective role for endogenous prostaglandin E2","volume":"345","author":"Pavord","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2024.08.008_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1164\/ajrccm.159.1.9804030","article-title":"Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation","volume":"159","author":"Gauvreau","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib61","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood-2005-07-2772","article-title":"Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses","volume":"107","author":"Feng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.alit.2024.08.008_bib62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjp.0706664","article-title":"Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation","volume":"147","author":"Kay","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.alit.2024.08.008_bib63","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.clinbiochem.2012.12.005","article-title":"Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD)","volume":"46","author":"Narayanankutty","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.alit.2024.08.008_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.03.046","article-title":"PGE(2) deficiency predisposes to anaphylaxis by causing mast cell hyperresponsiveness","volume":"146","author":"Rastogi","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.04.002","article-title":"Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor","volume":"136","author":"S\u00e4fholm","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib66","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaci.2012.02.007","article-title":"Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma","volume":"129","author":"Corrigan","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib67","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2005.10.037","article-title":"Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells","volume":"117","author":"Ying","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2 Pt 1","key":"10.1016\/j.alit.2024.08.008_bib68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1164\/ajrccm.161.2.9902034","article-title":"Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients","volume":"161","author":"Kowalski","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib69","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaci.2005.02.029","article-title":"Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis","volume":"115","author":"Perez-Novo","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib70","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2332\/allergolint.O-08-545","article-title":"Correlation between the prostaglandin D(2)\/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma","volume":"57","author":"Yoshimura","year":"2008","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib71","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2011.01.065","article-title":"Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma","volume":"128","author":"Roca-Ferrer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib72","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jaci.2013.12.1034","article-title":"Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease","volume":"133","author":"Laidlaw","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1164\/ajrccm.153.2.8564099","article-title":"Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma","volume":"153","author":"Szczeklik","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib74","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1164\/ajrccm.153.2.8564100","article-title":"Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma","volume":"153","author":"Sestini","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.anai.2011.09.022","article-title":"Smoking, environmental tobacco smoke, and aspirin-exacerbated respiratory disease","volume":"108","author":"Chang","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib76","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/all.12941","article-title":"Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA2 LEN) survey","volume":"71","author":"Makowska","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib77","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/thorax.58.7.585","article-title":"Exhaled leukotrienes and prostaglandins in COPD","volume":"58","author":"Montuschi","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2024.08.008_bib78","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.12077","article-title":"Levels of prostaglandin E(2) and Cysteinyl-leukotrienes in sputum supernatant of patients with asthma: the effect of smoking","volume":"43","author":"Kontogianni","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib79","first-page":"158","article-title":"Cigarette smoking, cyclooxygenase-2 pathway and cancer","volume":"1815","author":"Huang","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.alit.2024.08.008_bib80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jcp.20825","article-title":"Prostaglandin E(2) protects human lung fibroblasts from cigarette smoke extract-induced apoptosis via EP(2) receptor activation","volume":"210","author":"Sugiura","year":"2007","journal-title":"J\u00a0Cel Physiol"},{"key":"10.1016\/j.alit.2024.08.008_bib81","doi-asserted-by":"crossref","first-page":"L261","DOI":"10.1152\/ajplung.90593.2008","article-title":"Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products","volume":"298","author":"Profita","year":"2010","journal-title":"Am J Physiol Lung Cel Mol Physiol"},{"key":"10.1016\/j.alit.2024.08.008_bib82","article-title":"Smoking cessation as a possible risk factor for the development of aspirin-exacerbated respiratory disease in smokers","volume":"6","author":"Hayashi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib83","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaci.2021.06.016","article-title":"Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease","volume":"148","author":"Eid","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib84","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jaci.2004.07.013","article-title":"Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis","volume":"114","author":"Van Zele","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib85","doi-asserted-by":"crossref","first-page":"16477","DOI":"10.1074\/jbc.M705822200","article-title":"Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells","volume":"283","author":"Paruchuri","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.alit.2024.08.008_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.02.046","article-title":"Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps","volume":"130","author":"Takabayashi","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib87","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.anai.2020.11.002","article-title":"Insights into mast cell hyperplasia in aspirin-exacerbated respiratory disease from transcriptional profiling of polyp mast cells","volume":"126","author":"Martin","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb7221","article-title":"Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation","volume":"6","author":"Dwyer","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib89","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0091-6749(96)70167-7","article-title":"Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction","volume":"98","author":"O'Sullivan","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib90","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1365-2745.2002.01507.x","article-title":"A\u00a0comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma","volume":"32","author":"Higashi","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib91","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaci.2010.12.1108","article-title":"Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype","volume":"127","author":"Sanak","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib92","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jaci.2016.09.025","article-title":"Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease","volume":"139","author":"Cahill","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib93","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.alit.2016.10.001","article-title":"Increased airway hyperresponsiveness to adenosine in patients with aspirin intolerant asthma","volume":"66","author":"Isogai","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib94","first-page":"1515","article-title":"[Sodium cromoglycate nebulized solution has an acute bronchodilative effect in patients with aspirin-intolerant asthma (AIA)]","volume":"41","author":"Imokawa","year":"1992","journal-title":"Arerugi"},{"key":"10.1016\/j.alit.2024.08.008_bib95","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1164\/ajrccm.155.4.9105094","article-title":"Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium","volume":"155","author":"Robuschi","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib96","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib97","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12931-018-0909-6","article-title":"The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease","volume":"19","author":"Comhair","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.alit.2024.08.008_bib98","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/all.14620","article-title":"Adult-onset eosinophilic airway diseases","volume":"75","author":"Asano","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib99","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jaip.2024.01.029","article-title":"Absolute eosinophil counts in aspirin-exacerbated respiratory disease are distinctly elevated and correlate inversely with respiratory function","volume":"12","author":"Supron","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.11.023","article-title":"Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease","volume":"140","author":"Eastman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib101","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2222.2004.01968.x","article-title":"Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge","volume":"34","author":"Mita","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib102","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/cea.12096","article-title":"Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD","volume":"43","author":"Choi","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib103","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A\u00a0retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib104","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib105","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: a case series","volume":"9","author":"Martin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib106","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/lary.27564","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.alit.2024.08.008_bib107","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nature08636","article-title":"Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells","volume":"463","author":"Moro","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.alit.2024.08.008_bib108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.alit.2018.11.001","article-title":"Airway innate lymphoid cells in the induction and regulation of allergy","volume":"68","author":"Doherty","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib109","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaci.2016.09.011","article-title":"Innate lymphoid cells in allergic and nonallergic inflammation","volume":"138","author":"Morita","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.chest.2019.04.101","article-title":"Group 2 innate lymphoid cells in airway diseases","volume":"156","author":"Kato","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.alit.2024.08.008_bib111","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.alit.2014.12.006","article-title":"Immunopathology of chronic rhinosinusitis","volume":"64","author":"Kato","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib112","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.12.958","article-title":"Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines","volume":"140","author":"Salimi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib114","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jaci.2013.10.056","article-title":"Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells","volume":"133","author":"Xue","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/ajra.2014.28.4054","article-title":"Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease","volume":"28","author":"Johns","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.09.050","article-title":"Prostaglandin E(2) suppresses human group 2 innate lymphoid cell function","volume":"141","author":"Maric","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib117","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anai.2020.08.001","article-title":"Group 2 innate lymphoid cells in nasal polyposis","volume":"126","author":"Stevens","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib118","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.jaci.2015.04.028","article-title":"Role of platelets in allergic airway inflammation","volume":"135","author":"Idzko","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib119","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200702-214OC","article-title":"Allergen induces the migration of platelets to lung tissue in allergic asthma","volume":"177","author":"Pitchford","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.alit.2017.11.008","article-title":"Recent advances in understanding the roles of blood platelets in the pathogenesis of allergic inflammation and bronchial asthma","volume":"67","author":"Takeda","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.01.032","article-title":"Platelets constitutively express IL-33 protein and modulate eosinophilic airway inflammation","volume":"138","author":"Takeda","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib122","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaci.2015.05.041","article-title":"Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Mitsui","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib123","doi-asserted-by":"crossref","first-page":"16987","DOI":"10.1073\/pnas.1313185110","article-title":"Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes","volume":"110","author":"Liu","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.alit.2024.08.008_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.06.001","article-title":"A\u00a0trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease","volume":"143","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.03.030","article-title":"Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease","volume":"152","author":"Laidlaw","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib126","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.anai.2020.09.016","article-title":"Local immunoglobulin production in nasal tissues: a key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease","volume":"126","author":"Buchheit","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.734733","article-title":"Pathomechanisms of AERD-recent advances","volume":"2","author":"Lyly","year":"2021","journal-title":"Front Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaci.2016.11.015","article-title":"Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis","volume":"140","author":"Van Roey","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib129","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib130","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jaci.2017.01.022","article-title":"Microparticles in nasal lavage fluids in chronic rhinosinusitis: potential biomarkers for diagnosis of aspirin-exacerbated respiratory disease","volume":"140","author":"Takahashi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib131","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1398-9995.2004.00621.x","article-title":"Organization of secondary lymphoid tissue and local IgE formation to Staphylococcus aureus enterotoxins in nasal polyp tissue","volume":"60","author":"Gevaert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1398-9995.2010.02448.x","article-title":"Mucosal tissue polyclonal IgE is functional in response to allergen and SEB","volume":"66","author":"Zhang","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.02.020","article-title":"Oral steroids and doxycycline: two different approaches to treat nasal polyps","volume":"125","author":"Van Zele","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib134","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jama.2015.7544","article-title":"Medical therapies for adult chronic sinusitis: a systematic review","volume":"314","author":"Rudmik","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.alit.2024.08.008_bib135","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/lary.23486","article-title":"A\u00a0randomized trial of mupirocin sinonasal rinses versus saline in surgically recalcitrant staphylococcal chronic rhinosinusitis","volume":"122","author":"Jervis-Bardy","year":"2012","journal-title":"Laryngoscope"},{"key":"10.1016\/j.alit.2024.08.008_bib136","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2332\/allergolint.09-OA-0137","article-title":"One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma","volume":"59","author":"Ohta","year":"2010","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101950","article-title":"Real-life safety and efficacy of omalizumab in Japanese patients with severe allergic asthma who were subjected to dosing table revision or expansion: a post-marketing surveillance","volume":"64","author":"Asano","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.alit.2024.08.008_bib138","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.alit.2020.01.004","article-title":"Roles of omalizumab in various allergic diseases","volume":"69","author":"Okayama","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib139","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A\u00a0proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.alit.2024.08.008_bib141","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.08.008_bib142","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1939-4551-7-17","article-title":"New strategies with anti-IgE in allergic diseases","volume":"7","author":"Holgate","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.alit.2024.08.008_bib143","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2024.08.008_bib144","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2024.08.008_bib145","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib146","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-200161020-00008","article-title":"Omalizumab","volume":"61","author":"Easthope","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.alit.2024.08.008_bib147","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fce psilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib148","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib149","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2003.11.044","article-title":"Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils","volume":"113","author":"Lin","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib151","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","article-title":"Omalizumab treatment downregulates dendritic cell FcepsilonRI expression","volume":"112","author":"Prussin","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib152","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib153","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2014.02.005","article-title":"Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib154","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cea.12668","article-title":"Comparable actions of omalizumab on mast cells and basophils","volume":"46","author":"Serrano-Candelas","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib156","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1398-9995.2011.02557.x","article-title":"Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI\/ENDA(#) and GA2LEN\/HANNA","volume":"66","author":"Kowalski","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib157","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/bmj.1.5949.67","article-title":"Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients","volume":"1","author":"Szczeklik","year":"1975","journal-title":"Br Med J"},{"key":"10.1016\/j.alit.2024.08.008_bib158","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2008.09.048","article-title":"Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease","volume":"123","author":"Hope","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib159","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM200101113440215","article-title":"Celecoxib in patients with asthma and aspirin intolerance. The celecoxib in aspirin-intolerant asthma study group","volume":"344","author":"Dahlen","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.08.008_bib160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaci.2013.10.057","article-title":"Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials","volume":"134","author":"Morales","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6 Pt 1","key":"10.1016\/j.alit.2024.08.008_bib161","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1447","article-title":"The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin","volume":"148","author":"Israel","year":"1993","journal-title":"Am Rev Respir Dis"},{"issue":"6 Pt 1","key":"10.1016\/j.alit.2024.08.008_bib162","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1081-1206(10)62575-6","article-title":"Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics","volume":"85","author":"Stevenson","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib163","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","article-title":"The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy","volume":"147","author":"Stevens","year":"2021","journal-title":"Asthma & Immunology J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib164","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1164\/rccm.201809-1755OC","article-title":"Unique effect of aspirin therapy on biomarkers in aspirin-exacerbated respiratory disease. A prospective trial","volume":"200","author":"Cahill","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib165","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mai.2003.7","article-title":"Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"111","author":"Berges-Gimeno","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib166","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2007.06.047","article-title":"An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"121","author":"Shaker","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib167","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anai.2020.08.008","article-title":"Aspirin desensitization vs biologics for patients with aspirin-exacerbated respiratory disease","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib168","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib169","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaci.2006.09.011","article-title":"Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease","volume":"119","author":"Lee","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib170","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1016\/j.jaip.2020.06.063","article-title":"High discontinuation rates of peroral ASA treatment for CRSwNP: a real-world multicenter study of 171 N-ERD patients","volume":"8","author":"Laulajainen-Hongisto","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib171","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","article-title":"Acute and chronic systemic corticosteroid-related complications in patients with severe asthma","volume":"136","author":"Lefebvre","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib173","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/000348941112000304","article-title":"Revision rates after endoscopic sinus surgery: a recurrence analysis","volume":"120","author":"Mendelsohn","year":"2011","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.alit.2024.08.008_bib174","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib175","article-title":"Omalizumab-induced aspirin tolerance in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease patients is independent of atopic sensitization","volume":"10","author":"Quint","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib176","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.jaip.2023.04.033","article-title":"Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: a randomized comparative trial","volume":"11","author":"S\u00e1nchez","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib177","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1164\/rccm.202003-0783ED","article-title":"Does IgE have a role in aspirin-exacerbated respiratory disease?","volume":"201","author":"Busse","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib178","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1034\/j.1399-3003.2000.016003432.x","article-title":"Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma","volume":"16","author":"Szczeklik","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.08.008_bib179","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaci.2005.08.035","article-title":"Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma","volume":"116","author":"Mascia","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib180","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/all.14141","article-title":"Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis","volume":"75","author":"Celejewska-W\u00f3jcik","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib181","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1183\/09031936.03.00261903","article-title":"The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma","volume":"22","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.08.008_bib182","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2222.2011.03880.x","article-title":"Obesity and aspirin intolerance are risk factors for difficult-to-treat asthma in Japanese non-atopic women","volume":"42","author":"Fukutomi","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib183","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update. Available at: https:\/\/ginasthma.org\/2024-report\/."},{"key":"10.1016\/j.alit.2024.08.008_bib184","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating committee expert panel working group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.alit.2023.02.006","article-title":"Executive summary: Japanese guidelines for adult asthma (JGL) 2021","volume":"72","author":"Niimi","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib186","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/all.12629","article-title":"NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity","volume":"70","author":"Morales","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib187","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/ajrccm.165.1.2010080","article-title":"Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial","volume":"165","author":"Dahlen","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"4 Pt 1","key":"10.1016\/j.alit.2024.08.008_bib188","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1164\/ajrccm.157.4.9707089","article-title":"Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics","volume":"157","author":"Dahl\u00e9n","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib189","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1046\/j.1398-9995.2003.00351.x","article-title":"Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo","volume":"59","author":"Micheletto","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib190","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1074\/jbc.C113.453704","article-title":"Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand","volume":"288","author":"Kanaoka","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.alit.2024.08.008_bib191","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00405-016-4366-x","article-title":"Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study","volume":"274","author":"Gudziol","year":"2017","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.alit.2024.08.008_bib192","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/alr.22249","article-title":"Patterns of olfactory dysfunction in chronic rhinosinusitis identified by hierarchical cluster analysis and machine learning algorithms","volume":"9","author":"Morse","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.alit.2024.08.008_bib193","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.iac.2012.11.002","article-title":"Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease","volume":"33","author":"Mullol","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.alit.2024.08.008_bib194","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib195","article-title":"Hearing loss and middle ear symptoms in aspirin-exacerbated respiratory disease","volume":"7","author":"Mullur","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib196","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaci.2021.12.782","article-title":"Advances in chronic rhinosinusitis in 2020 and 2021","volume":"149","author":"Xu","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"Suppl S29","key":"10.1016\/j.alit.2024.08.008_bib197","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.alit.2024.08.008_bib198","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","article-title":"Chronic rhinosinusitis in Europe--an underestimated disease. A GA(2)LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib199","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0091-6749(80)90143-8","article-title":"Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges","volume":"66","author":"Stevenson","year":"1980","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib200","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib201","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1164\/rccm.201909-1869OC","article-title":"Urinary leukotriene E(4) and prostaglandin D(2) metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. A clinical observational study","volume":"203","author":"Kolmert","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib203","first-page":"123","article-title":"[A case of aspirin-exacerbated respiratory disease complicated by refractory variant angina, which showed excellent response to steroid treatment]","volume":"65","author":"Naito","year":"2016","journal-title":"Arerugi"},{"key":"10.1016\/j.alit.2024.08.008_bib204","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.ijcard.2014.05.008","article-title":"Kounis syndrome caused by aspirin-induced asthma","volume":"175","author":"Oshima","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.alit.2024.08.008_bib205","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1067\/mai.2002.121700","article-title":"Myocardial ischemia possibly mediated by cysteinyl leukotrienes","volume":"109","author":"Szczeklik","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib206","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"Swierczynska-Krepa","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib207","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-020-00423-3","article-title":"Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report","volume":"16","author":"Caruso","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib208","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/01.CIR.76.2.480","article-title":"Leukotriene C4- and D4-induced diffuse peripheral constriction of swine coronary artery accompanied by ST elevation on the electrocardiogram: angiographic analysis","volume":"76","author":"Tomoike","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.alit.2024.08.008_bib209","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1172\/JCI19785","article-title":"Mast cells are required for experimental oral allergen-induced diarrhea","volume":"112","author":"Brandt","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2024.08.008_bib210","first-page":"837","article-title":"First-aid treatment of anaphylaxis to food: focus on epinephrine","volume":"113","author":"Simons","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib211","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJM198510313131807","article-title":"Increased adventitial mast cells in a patient with coronary spasm","volume":"313","author":"Forman","year":"1985","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.08.008_bib212","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00000433-198612000-00015","article-title":"Fatal nonatherosclerotic myocardial infarction in a young man with allergic bronchial asthma","volume":"7","author":"van der Bel-Kahn","year":"1986","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1016\/j.alit.2024.08.008_bib213","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1016\/j.jaip.2021.06.002","article-title":"Clinicopathologic correlations in eosinophilic gastrointestinal disorders","volume":"9","author":"Pesek","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib214","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jaci.2014.07.026","article-title":"Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome","volume":"134","author":"Caldwell","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib215","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.alit.2019.03.003","article-title":"Eosinophilic gastrointestinal diseases - pathogenesis, diagnosis, and treatment","volume":"68","author":"Kinoshita","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib216","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.cgh.2017.08.043","article-title":"Videocapsule endoscopy identifies small bowel lesions in patients with eosinophilic enteritis","volume":"16","author":"Nguyen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.alit.2024.08.008_bib217","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1365-2133.2003.05090.x","article-title":"Pattern analysis of human cutaneous mast cell populations by total body surface mapping","volume":"148","author":"Weber","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2024.08.008_bib218","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2024.08.008_bib219","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.alit.2024.08.008_bib220","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib221","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1398-9995.2009.02144.x","article-title":"After 6 years with Xolair; a 3-year withdrawal follow-up","volume":"65","author":"Nopp","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2008.09.050","article-title":"Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations","volume":"123","author":"Slavin","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib223","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.anai.2015.08.013","article-title":"A\u00a012\u00bd-year journey of a patient with Samter triad syndrome and sporadic omalizumab use","volume":"115","author":"Ardusso","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib224","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.10-1194","article-title":"Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review","volume":"139","author":"Rodrigo","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.alit.2024.08.008_bib225","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib226","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1385\/CRIAI:29:1:031","article-title":"Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody","volume":"29","author":"Deniz","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib227","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib229","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib230","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib231","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American academy of allergy, asthma & Immunology\/American college of allergy, asthma & Immunology omalizumab-associated anaphylaxis joint task force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib232","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.jaci.2016.12.953","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials","volume":"139","author":"Iribarren","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib234","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaci.2007.10.040","article-title":"Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment","volume":"121","author":"Ruppert","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib235","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib236","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.alit.2017.10.008","article-title":"Th1-related disease development during omalizumab treatment: two cases with severe asthma","volume":"67","author":"Hayashi","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.08.008_bib237","first-page":"315","article-title":"Cutaneous sarcoidosis in a patient with severe asthma treated with omalizumab","volume":"22","author":"Yung","year":"2015","journal-title":"Can Respir J"},{"key":"10.1016\/j.alit.2024.08.008_bib238","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1016\/j.jaip.2021.05.027","article-title":"Rheumatoid arthritis-like polyarthralgia after the initiation of omalizumab treatment: a case series","volume":"9","author":"To","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib239","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib240","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/362248a0","article-title":"Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses","volume":"362","author":"Minty","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.alit.2024.08.008_bib241","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.coi.2021.12.001","article-title":"T\u00a0follicular helper cells in IgE-mediated pathologies","volume":"74","author":"Gowthaman","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib242","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cea.13514","article-title":"Blockade of IL-4R\u03b1 inhibits group 2 innate lymphoid cell responses in asthma patients","volume":"50","author":"Patel","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2024.08.008_bib243","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.08.008_bib244","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.08.008_bib245","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.alit.2024.08.008_bib246","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2024.08.008_bib247","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.alit.2024.08.008_bib248","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib249","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.08.008_bib250","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.08.008_bib251","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cyto.2015.05.019","article-title":"Mast cell production and response to IL-4 and IL-13","volume":"75","author":"McLeod","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.alit.2024.08.008_bib252","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01335-2022","article-title":"Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease","volume":"61","author":"Schneider","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.08.008_bib253","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","article-title":"Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease","volume":"126","author":"Mustafa","year":"2021","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893024001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893024001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:47:53Z","timestamp":1762368473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893024001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":253,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1323893024001084"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2024.08.008","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Allergology. Published by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}